Phase 3 Readout
SPRY: Phase 3 Topline: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With
December 29, 2028 · jnj-56021927. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 29, 2028
- Company
- ARS Pharmaceuticals, Inc. (SPRY)
- Drug
- jnj-56021927
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With
- Drug
- jnj-56021927
- Indication
- Prostatic Neoplasms